Erratum to "A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer" [Gynecologic Oncology 159 (2020) 827-838].

Laychiluh Bantie , Solomon Tadesse , Jimma Likisa , Mingfeng Yu , Benjamin Noll , Gary Heinemann , Noor A Lokman , Carmela Ricciardelli , Martin K Oehler , Andrew Beck , Rupal Pradhan , Robert Milne , Hugo Albrecht , Shudong Wang

Gynecol Oncol

Drug Discovery and Development, Cancer Research Institute and Clinical and Health Sciences, University of South Australia, Australia. Electronic address:

Published: October 2021

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

Download full-text PDF
Source

http://dx.doi.org/10.1016/j.ygyno.2021.07.018 DOI Listing

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ygyno.2021.07.018	DOI Listing

Publication Analysis

Top Keywords

erratum first-in-class

first-in-class cdk4

cdk4 inhibitor

inhibitor demonstrates

demonstrates vitro

vitro ex-vivo

ex-vivo vivo

vivo efficacy

efficacy ovarian

ovarian cancer"

A PHP Error was encountered